Kies je regio

Selecteer de regio die het beste past bij je locatie of voorkeuren.

International

Kies je sitetaal

Deze instelling regelt de taal van de gebruikersinterface, inclusief knoppen, menu's en alle tekst op de site. Selecteer je voorkeurstaal voor de beste browse-ervaring.

Kies de talen voor vacatures

Selecteer de talen voor vacatures die je wilt zien. Deze instelling bepaalt welke vacatures aan jou worden getoond.

Pieris Pharmaceuticals GmbH

Freising, Duitsland

Maak een e-mailalert aan

Website bezoeken

Over de werkgever

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin^® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.

Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).